Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SLO-PHYLLIN vs AMINOPHYLLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.
Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., COPD, emphysema, chronic bronchitis),Off-label: Apnea of prematurity,Off-label: Adjunctive therapy in acute asthma exacerbations (rarely used)
Treatment of acute bronchial asthma, reversible bronchospasm associated with chronic bronchitis and emphysema,Neonatal apnea (off-label),Adjunctive therapy in COPD exacerbations
Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
Terminal elimination half-life is approximately 3-8 hours in adults (non-smokers, healthy), 1-5 hours in smokers, and 20-30 hours in neonates. Clinical context: Half-life is prolonged in hepatic cirrhosis, heart failure, and with certain drug interactions (e.g., cimetidine, ciprofloxacin).
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Primarily hepatic via CYP450 enzymes: CYP1A2, CYP2E1, CYP3A4; metabolite: 1,3-dimethyluric acid. Approximately 10% excreted unchanged in urine.
Hepatic demethylation and oxidation via cytochrome P450 isoenzymes (CYP1A2, CYP3A4, CYP2E1); approximately 10% excreted unchanged in urine.
Renal: ~10% unchanged; hepatic metabolism accounts for ~90% of elimination, with metabolites excreted in urine. Fecal: <5%.
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Approximately 40% bound to albumin; binding is saturable and decreased in neonates, hepatic disease, and acidosis.
~40% bound to plasma proteins (primarily albumin).
0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Distributes evenly into body water and highly perfused tissues; Vd increased in premature infants and decreased in obesity.
0.5 L/kg (range 0.3–0.7 L/kg); increased in neonates, cirrhosis, and malnutrition; reflects distribution into total body water.
Oral immediate-release: 96-100%; oral sustained-release (Slo-Phyllin): 90-100% relative to immediate-release; rectal: variable (~80-100% for enema); IV: 100%.
Oral (immediate-release): 100% (well absorbed); rectal: ~80% (variable); IV: 100%.
No specific dose adjustment is required for renal impairment. However, monitoring serum concentrations is recommended due to altered clearance in severe renal failure (GFR <10 m L/min).
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25% and monitor levels; GFR <10 m L/min: reduce dose by 50% and monitor levels closely.
Child-Pugh Class B or C: Reduce dose by 50% and monitor serum concentrations closely. Avoid use in severe hepatic impairment if possible.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: use with extreme caution, reduce dose by 90% or consider alternative.
Starting dose: 5 mg/kg/day orally in divided doses every 6 hours (immediate-release) or every 12 hours (sustained-release). Titrate based on serum concentrations, targeting 5-15 mcg/m L. Maximum dose: 24 mg/kg/day or 900 mg/day, whichever is less.
Loading dose: 5-6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: infants <1 year: 0.4-0.7 mg/kg/hr IV; children 1-9 years: 0.8-1.0 mg/kg/hr IV; children >9 years: 0.6-0.8 mg/kg/hr IV. Oral: immediate-release 5 mg/kg every 6 hours; sustained-release not recommended under 6 years.
Start at low end of dosing range (e.g., 200-300 mg/day sustained-release). Monitor serum concentrations carefully as clearance is reduced in elderly patients, increasing risk of toxicity.
Reduce maintenance dose by 50-75% compared to younger adults; monitor serum theophylline levels closely; typical starting maintenance: 0.3-0.5 mg/kg/hr IV; avoid doses >400 mg/day oral.
No FDA boxed warning.
No specific FDA boxed warning for aminophylline; however, theophylline (its active metabolite) has a narrow therapeutic index and requires serum concentration monitoring to avoid toxicity.
Concurrent illness (fever, influenza), hepatic impairment, elderly, and smoking alter metabolism; narrow therapeutic index (10-20 mcg/m L); monitor serum levels; risk of seizures, arrhythmias, and death with toxicity; reduce dose with CYP1A2 inhibitors (cimetidine, fluoroquinolones, macrolides) or inducers (smoking, rifampin, phenytoin); caution in peptic ulcer disease, seizure disorders, cardiac arrhythmias.
Narrow therapeutic index; monitor serum concentrations (target 10-20 mcg/m L); caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, cardiac arrhythmias; use with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, fluvoxamine) or induce metabolism (e.g., smoking, rifampin, phenytoin).
Hypersensitivity to theophylline or any component,Pre-existing arrhythmia (especially tachyarrhythmias),Active seizure disorder not adequately controlled
Hypersensitivity to aminophylline, theophylline, or ethylenediamine; active peptic ulcer disease; uncontrolled seizure disorders; severe cardiac arrhythmias (unless patient is undergoing monitored treatment).
Avoid high-fat meals as they may alter absorption of sustained-release preparations. Limit caffeine-containing foods and beverages. Avoid charcoal-broiled foods, which can increase metabolism.
High-fat meals can delay absorption of aminophylline. Avoid charred meat and foods containing large amounts of caffeine. Cruciferous vegetables (broccoli, brussels sprouts) may increase metabolism. Maintain consistent dietary intake of protein and carbohydrates as changes can affect theophylline clearance.
Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester exposure is not associated with major congenital malformations. Third trimester use may lead to transient neonatal apnea, jitteriness, or tachycardia due to placental transfer. No increased risk of preterm birth or low birth weight has been consistently demonstrated.
Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal asthma control benefits outweigh risks. Third trimester: Risk of neonatal apnea, irritability, and tachycardia if maternal levels are high; avoid toxic levels.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach therapeutic concentrations if maternal doses are high. Breastfeeding is generally considered compatible, but monitor the infant for signs of theophylline toxicity (e.g., irritability, insomnia, tachycardia).
Aminophylline is excreted into breast milk; the M/P ratio (milk-to-plasma ratio) is approximately 0.6-0.8. Infant exposure is low (about 1-10% of maternal weight-adjusted dose). Use with caution; monitor infant for irritability and sleep disturbance. Generally considered compatible with breastfeeding.
Pregnancy may decrease theophylline clearance by 20-30%, particularly in the third trimester, due to reduced hepatic metabolism. Dose adjustments may be needed to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; reduce dose accordingly to avoid toxicity.
Pregnancy reduces theophylline clearance by 30-50% due to decreased hepatic metabolism and increased volume of distribution. Dose adjustments may be needed: reduce dose by 30% in the third trimester or monitor serum concentrations closely to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; readjust accordingly.
Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Adjust dose in patients with heart failure, liver disease, or on CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Do not crush or chew sustained-release tablets. Cigarette smoking induces metabolism, requiring higher doses.
Aminophylline is a bronchodilator composed of theophylline and ethylenediamine. The ethylenediamine component can cause hypersensitivity reactions. Monitor theophylline serum levels (target 10-20 mcg/m L). Use with caution in patients with cardiac arrhythmias, seizures, or peptic ulcer disease. Avoid in patients with porphyria. Cimetidine, ciprofloxacin, and macrolides can increase theophylline levels. Smoking induces metabolism, requiring higher doses.
Take this medication exactly as prescribed, usually every 8-12 hours.,Do not crush or chew the tablets; swallow them whole.,Avoid excessive caffeine intake (coffee, tea, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, or irregular heartbeat.,Do not change brands or formulations without consulting your doctor.
Take this medication exactly as prescribed, with or without food.,Do not crush or chew extended-release formulations.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, energy drinks) as it may increase side effects.,Report symptoms such as rapid heart rate, persistent nausea/vomiting, insomnia, or seizures immediately.,Do not stop abruptly without consulting your doctor.,Keep a regular dosing schedule to maintain consistent blood levels.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SLO-PHYLLIN vs AMINOPHYLLIN, answered by our medical review team.
SLO-PHYLLIN is a Xanthine Bronchodilator that works by SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.. AMINOPHYLLIN is a Xanthine Bronchodilator that works by Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SLO-PHYLLIN and AMINOPHYLLIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SLO-PHYLLIN is: Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of AMINOPHYLLIN is: Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SLO-PHYLLIN and AMINOPHYLLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SLO-PHYLLIN is classified as Category C. Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester expos. AMINOPHYLLIN is classified as Category C. Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal ast. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.